MENU
+Compare
SAGE
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$7.78
Change
-$0.08 (-1.02%)
Capitalization
477.71M

SAGE Sage Therapeutics Forecast, Technical & Fundamental Analysis

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines... Show more

SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SAGE with price predictions
Apr 01, 2025

SAGE's Stochastic Oscillator descending into oversold zone

The Stochastic Oscillator for SAGE moved into oversold territory on April 01, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 01, 2025. You may want to consider a long position or call options on SAGE as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SAGE advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SAGE moved out of overbought territory on March 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for SAGE turned negative on April 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SAGE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SAGE broke above its upper Bollinger Band on March 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.027) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (11.442) is also within normal values, averaging (251.391).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SAGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SAGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SAGE is expected to report earnings to fall 36.24% to -99 cents per share on May 06

Sage Therapeutics SAGE Stock Earnings Reports
Q1'25
Est.
$-0.99
Q4'24
Missed
by $0.06
Q3'24
Beat
by $0.01
Q2'24
Missed
by $0.06
Q1'24
Missed
by $0.15
The last earnings report on February 11 showed earnings per share of -155 cents, missing the estimate of -150 cents. With 823.42K shares outstanding, the current market capitalization sits at 477.71M.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and medicines for central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
215 First Street
Phone
+1 617 299-8380
Employees
487
Web
https://www.sagerx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DRDIX25.80N/A
N/A
Dearborn Partners Rising Dividend I
ADOZX20.74N/A
N/A
Alger Dynamic Opportunities Z
WLGRX31.00N/A
N/A
Macquarie Large Cap Growth Fund R
WOFDX55.12N/A
N/A
Allspring Opportunity Admin
GIRGX21.15N/A
N/A
Goldman Sachs U.S. Equity ESG Inv

SAGE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SAGE has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SAGE jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAGE
1D Price
Change %
SAGE100%
-1.13%
AXON - SAGE
42%
Loosely correlated
+2.90%
HRMY - SAGE
38%
Loosely correlated
-2.32%
KZR - SAGE
36%
Loosely correlated
-7.58%
PHIO - SAGE
35%
Loosely correlated
-5.38%
THRD - SAGE
34%
Loosely correlated
-3.17%
More